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Reports of the results of electrophysiologic testing of
antiarrhythmic regimens have concentrated on induci-
bility of ventricular tachycardias during drug treatment.
Many drug regimens, however, affect the tachycardia
but fail to prevent its initiation. In this study, 258 pa-
tients who underwent serial e1ectrophysiologic studies
were followed up. The patients were divided into three
groups on the basis of the results of electrophysiologic
testing. Group 1 included patients in whom the initiation
of ventricular tachycardia was prevented by the drug
regimen. In groups 2 and 3 the ventricular tachycardia
was still inducible with the discharge drug regimen. In
group 2, the drug regimen demonstrated a beneficial
response (that is, the tachycardia cycle length increased
by > 100 ms and the tachycardia did not produce severe
symptoms). In group 3, the regimen did not produce a
beneficial response.
The ability to prevent the initiation of a sustained ventricular
tachyarrhythmia by programmed stimulation has been shown
to predict antiarrhythmic drug efficacy. The inability to pre-
vent the initiation of sustained ventricular tachycardia, on
the other hand, is not always associated with a poor clinical
outcome. Previous reports (1-13) of the results of electro-
physiologic testing have highlighted the concepts of indu-
cibility and noninducibility (1-9), the number of induced
ventricular complexes (10, II), the ease of tachycardia in-
duction (I, II) or the presence or absence of repetitive ven-
tricular forms in response to programmed stimulation (10-13)
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During follow-up, recurrence of sustained ventricular
tachycardia occurred in 7 (7%) of 103 group 1 patients
but in 20 (39%) of 51 and 52 (50%) of 104 group 2 and
3 patients, respectively. However, the total mortality and
sudden death mortality rates were substantially reduced
in group 2 (12 and 4%, respectively) compared with
group 3 (39 and 34%). In fact, the total mortality and
sudden death mortality in groups 1 and 2 were not sig-
nificantly different. Thus, under certain circumstances,
a drug regimen that produces a beneficial response may
be an acceptable clinical alternative, particularly when
no regimen prevents induction of ventricular tachycar-
dia.
(J Am Coil CardioI1987;10:83-9)
as predictors of the clinical efficacy of a particular drug
regimen. The present study examined patients whose ar-
rhythmias remained inducible at electrophysiologic study to
determine if a defined "improvement" in the characteristics
of the induced ventricular tachycardia could predict arrhyth-
mia recurrence or patient survival, or both.
Methods
Study patients. The initial patient group comprised 291
consecutive patients who were referred for electrophysio-
logic evaluation in whom sustained ventricular tachycardia
or ventricular fibrillation was induced during a baseline study.
Twelve of these patients were treated surgically immediately
after drug therapy evaluation and were therefore excluded
from study. All other patients had at least one drug follow-
up study before discharge. Sixteen patients were discharged
on an antiarrhythmic regimen not tested at follow-up study
and were also excluded from study. One patient was ex-
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c1uded because catheter manipulation initiated ventricular
tachycardia both in the baseline and in the follow-up studie s.
Two patient s refused follow-up study before selection of an
effective medical regimen and two were lost to follow-up
after hospital discharge. The final study group compri sed
258 patient s.
The patients ranged in age from 15 to 86 years (mean
61). Of the 210 (81%) who had coronary artery disease ,
205 (98%) had sustained a previous myocardial infarction .
Nineteen of these infarctions had taken place < 6 weeks
before the time of initial evaluation . The remaining patient s
had a variety of heart diseases (Table I) . Ejection fraction
ranged from 7 to 83% (mean 29%).
Indications for electrophys iologic study included recur-
rent sustained ventricular tachycardia (145 patients), syn-
cope of unknown origin (43 patients), symptomatic non-
sustained ventricular tachycardia (35 patients), out of hospital
cardiac arrest (33 patients) and tachycardia or palpitation of
unkno wn origin (2 patients). Before electroph ysiologic test-
ing, patient s had undergone zero to six empiric drug trials
that were unsuccessful because of intolerance or ineffec-
tiveness .
Electrophysiologic study. Written informed consent was
obtained from each patient before study. Electrophysiologic
studies were completed at baseline in a postabsorpti ve state
with light diazepam sedation after all antiarrh ythmic med-
ications had been discontinued for a minimum of five half-
lives. Beta-adrenergic blocking agents, digitalis glycosides
and calcium channel blockers were continued throughout
electrophysiologic testing if administered for nonarrh ythmic
indications.
Multiple electrode catheters were inserted percutaneously
under local bupivacaine (0 .25%) anesthesia and were po-
sitioned with fluoroscopic guidance . Surface electrocardio-
graphic (ECG) leads I, aVF and V I and intracardiac elec-
trograms were displayed on an oscilloscope (Electronics for
Medicine VR 16) and were recorded on magnetic analog
tape . Real-time recordings at paper speeds of 100 to 250
mm/s were obta ined using an ink jet record er (Siemens-
Elema mingograf) .
Programmed ventricular stimulation included the intro-
duction of single, double and triple extra stimuli from the
right ventricular apex durin g normal sinus rhythm and ven-
tricular pacing at cycle lengths of 600 and 450 ms. The
stimulation protocol was repeated at the right ventricular
Table 1. Type of Heart Disease in 258 Patients
Co ronary artery disease
Remote myoca rdial infarction (>6 weeks)
Recent myocard ial infarction «6 wee ks)
No myocardial infarction
Ca rdiomyopathy
Valvu lar heart disease
No organic disease
210
186
19
5
29
7
12
outflow tract if no sustained arrhythmia was induced at the
apex . Left ventricular stimulation at two sites was performed
in patients with documented sustained ventricular tachy-
cardia or previous cardiac arrest if no arrhythmias could be
initiated by right ventricular stimulation. When the mor-
phology and rate of the clinical arrhythmia were available,
they were correlated with those characteristics of the induced
arrhythmias and assessment s were made on the clinical ar-
rhythmias.
The complete stimulation protocol was repeated at both
right ventricular sites at follow-up studies unless a sustained
arrhythmia was initiated reproducibly before completion of
the protocol. A single induction was accepted if cardio-
version was required for arrhythmia termination. Left ven-
tricular stimulation was performed only in patients in whom
it had been required for arrhythmia initiation in the baseline
study.
Serial electrophysiologic testing in all patients proceeded
with the intention of eliminating inducible ventricular tachy-
cardia or fibrillation. A patient was discharged on a regimen
that did not prevent initiation of ventricular tachycardia or
fibrillation only after failure of all applicable regimens.
Definitions. Sustained ventricular tachycardia was de-
fined as ventricular tachycardi a of ::::30 seconds' duration
or requiring termination before 30 seconds because of hemo-
dynamic intolerance.
ventricular fibrillati on was defined as the initiated ar-
rhythmia jf within 3 seconds after initiation of a sustained
ventricular tachyarrhythmia, typical ventricular fibrillation
was present in any surface ECG \cad .
Nonsustained ventricular tachycardia was defined as
spontaneously terminating ventricular tachycardia lastin g
longer than six complexes but < 30 seconds.
Noninducible was defined as fewer than 16 complexes
of ventricular tachycardia initiated using the complete stim-
ulation protocol.
Severe symptoms during ventricular tachycardia in-
cluded syncope, near syncope, dizziness, angina or dys-
pnea. Mild symptoms during ventricular tachycardia in-
cluded only palpitation.
A " beneficial response" on antiarrhythmic therapy was
prospectively defined as inducible sustained ventricular
tachycardia at follow-up study with an increase in cycle
length of :::: 100 ms comp ared with baseline and the absence
of severe symptoms during the induced tachycardia. If the
originally induced arrhythmia was ventricular fibrillation , a
beneficial response at follow-up study was considered to be
inducible sustained ventricular tachycardia with a cycle length
of ::::300 ms that was not associa ted with severe symptoms.
Term ination of ventricular tachycardia had to be accom-
plished with programmed stimulation or overdrive pacing
for a beneficial response to be present.
Sudden death was defined as an unexpected witnessed
death occurring within I hour of the onset of symptoms
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Table 2. Follow-up Dru g Therapy Employed in 258 Patients
Group I Group 2 Group 3
(n = 103) (n = 51) (n = 104) Total
Amiodarone 25 29 79 133
Quinidine 21 I () 22
Procainamide 16 I 4 21
Amiodarone and procainamide 4 5 7 16
Flecainide 5 7 3 15
Quinidine and mexiletine 9 2 2 13
Quinidine and tocainide 4 3 2 9
Mexiletine 4 0 1 5
Procainamide and mcxiletine 2 I 0 3
Beta-receptor blocker 3 () () 3
Bepridil 2 0 1 3
Procainamide and tocainide 1 1 () 2
Disopyramide 2 0 0 2
Amiodarone and mexiletine () 1 1 2
Indecainide 0 0 2 2
Phenytoin 2 0 0 2
Amiodarone and quinidine 0 0 I
Amiodarone and tocainide 0 () I
Tocainide I () ()
Sota lol I 0 0
Bethanidine I 0 0
representing a catas trophic change in the state of hea lth not
otherwise explained by obviou s eve nts. If the dea th was not
witne ssed , it was considered sudden if the patient was seen
within the prior 12 hours and had been free of chest pain
and other significant symptoms and if the patient's overall
clinical status had been stable. If a patient was successfully
resuscitated from an arrhythmic event (out of hospital car-
diac arrest), that event was considered a sudden cardiac
dea th for statistical purposes.
Follow-up. Antiarrhythmic medications used in this study
are tabulated in Table 2. Patient s were followed up in a
research arrhyth mia cl inic if they were taking an investi -
gational drug or by their private physician if they were taking
conventional agen ts. Follow-up data were also obtained
through telephone con tact with patients or their physician s
and through yearly questionnaires. All deaths were inves-
tigated using medical or hospital records, interviews with
observers and postmortem findings when they were avail -
able. Symptomatic episode s consistent with recurrent ar-
rhythmia were investigated with Holter ECG monitoring,
transtelephonic ECG transmissions or in-hospital telemetric
monitoring , or all three .
The duration offollow-up was calculated from the date
cf electrophysiologic study to each of three clinical end
points: I) arrhythmia recurrence, 2) sudden cardiac death,
and 3) death from any cause (total mortality) . When mod-
ifications in antiarrhythmic therapy were made, patients were
censored as of the date of change in their medication . If a
medication was discontinued because of intolerable side
effec ts, the patient was censored on the date the drug was
discontinued . If death occurred without a documented re-
currence (death from nonarrhythmic causes), the patie nt was
censored on the date of death . In analyzing recurrences ,
patients who died suddenly were considered to have had
recurrence on the date of death . The most recent clinic visit
before Apri l 29. 1986 was the analy sis end point for those
patients who did not reach other end points . Life table ana l-
ysis was applied to each of the three clinical end point s and
Table 3. Baseline , Demographic and Fo llow-up Data in 258 Patients
Mean Mean Follow-up (mo)
Age EF Initial
Group N (yr) Male/Female (%) VTCL Mean Range
1 103 61 92/11 36 257 ± 68 23.7 0.2 to 57.4
2 51 61 44/7 25 272 ± 54 19.9 1.0 to 48.9
3 104 61 88/16 25 279 ± 65 18.5 0.1 to 49.2
EF = ejection fraction: N = number of patients: VTCL = ventricular tachycardia cycle length (rns).
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DAYS
Results
the Mantel-Cox and Breslow statistics were used to test for
differen ces between survival curves.
duced (group I) and 155 had inducible sustained ventricular
tachycardia . Fifty-one of the latter patient s (group 2) dem-
onstrated a " beneficial respon se" ; the remaining I04 (group
3) did not meet criteria for a beneficial respon se . Fort y-five
of the group 3 patients had only mild symptoms durin g
ventricular tachycardia at follow-up study but the tachy-
cardia cycle length increased by < 100 ms. Thirteen patients
had an increase in tachycard ia cycle length of 2: 100 ms but
had severe symptoms durin g ventricular tachycardia. Forty-
five patients failed to show an increase in ventricular tachy-
cardia cycle length of 100 ms and had severe symptoms
during induced ventricular tachycardia. One patient had a
ventr icular tachycardia cycle length increase of 110 ms and
had mild symptoms during ventricular tachycardia, but car-
dioversion was required for term ination .
Clinical variables of the three groups are compared in
Table 3 . In patients who had inducible sustained ventri cular
tachycardia at follow -up study (groups 2 and 3), no differ-
ences were noted in age , sex, left ventricular eject ion frac-
tion , incidence of coronary artery disease or ventricular
tachycardia cycle length observed at basel ine study. There
was no difference in the proport ion of patients in whom
severe symptoms were produced by arrhythmia during the
baseline study among the groups (group I = 94%; group
2 = 94%; group 3 = 92%).
Arrhythmia recurrence and mortality. Using arrh yth-
mia recurrence as a clinical end point , the recurrence-free
interval was not significantly different between groups 2 and
3. Arrhythmias recurred in 32% of group 2 and 35% of
group 3 patient s within I year and in 39 and 53 %, respec-
tively, within 2 years of follow-up. Group I, however , had
significantly lower recurrence rates at I and 2 year follow-
up (4 and 6%, respectively) (Fig. I, Table 4). Life table
analysis demonstrated a significant difference between group
I and groups 2 and 3 (p < 0 .0001) .
I
1460
6
.. . .. 0
o
i I
25
5
6
I ,
1095
39
II
26
i 7 30 Ii I I365
...._---
-----------"
---------,
---,
'------
70
30 GROUP, N'
I ---- 65
20 2-- 25
I 3 52
o iii i
80
90
100
u.
o
uJ
w
a:
u,
w~~>
!Z !Z 60
WwU a:
a: a:~ a 50
~ll! 40
f;i
...J
:;)
~
:;)
U
Figure 1. Life table analysis of ventricular tachycardia (VT) re-
currences in patient groups I, 2 and 3. Group I differed signifi-
cantly from group 2 (p < 0.000 I) and from group 3 (p < 0.000 I)
but groups 2 and 3 were not significantly different. The numbers
at the bottom of the graph indicate the number of patients who
remained available for analysis at years I, 2, 3 and 4.
Baseline electrophysiologic studies. All 258 patients
had induc ible sustained ventri cular tachycardia (n = 22 1)
or ventricular fibrillat ion (n = 37) at the basel ine electro -
physiologic study. At baseline , the arrhythmia produced
severe symptoms in 241 patients and mild symptoms in 17.
In the 241 patients with severe symptoms , 221 had syncope
or near syncope and the remainder had angina or dyspnea.
Follow-up electrophysiologic studies. At follow-up
study, 103 patients did not have sustained arrhythmia in-
Table 4. Ventricular Tachycardia Characteristics at Follow-up Study and Clinical Follow-up in
258 Patients
Mortality
N Recurrences Total SO
Group
I (Noninducible) 103 7(7%) 13(13%) 3(3%)
2 (Beneficial response) 5 1 20(39%) 6(12%) 2(4%)
3 (No benefit) 104 52(50%) 41(39%) 35(34%)
Patients (n = 155) with inducible
VT during follow-up study (groups 2 and 3)
Mild symptoms 97 46(47%) 25(26%) 19(20%)
VTCL increase < 100 ms and mild 46 26(57%) 19(41%) 17(37%)
symptoms
VTCL increase > 100 ms and severe 13 10(77%) 6(46%) 5(39%)
symptoms
VTCL > 400 ms 50 23(46%) 13(26%) 7(14%)
VTCL > 450 ms 24 12(50%) 6(25%) 3(13%)
SD = sudden death ; VT = ventricular tachycardi a; VTCL = ventricular tachycardi a cycle length .
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Figure3. Life table analysis of sudden death events during clinical
follow-up. Groups I and 2 were not significantly different from
each other, but group 3 differed significantly from group 2 (p <
0.0(03) and group I (p < 0.0(01). The numbers at the bottom
of thegraph indicate thenumber ofpatients who remained available
for analysis at years I, 2, 3 and 4.
Figure 2. Life table analysis of total mortality during clinical
follow-up. Groups I and 2 were not significantly different from
each other, but group 3 differed significantly from group 2 (p <
0.002) and from group I (p< 0.0001). Thenumbers at thebottom
ofthegraph indicate thenumber ofpatients who remained avai lable
for analysis at years I, 2, 3 and 4.
recurrences during the follow-up period; in group 3, in which
no beneficial response was achieved, 52 (50%) of 104 pa-
tients had recurrent arrhythmias. Six patients (12%) in group
2 died and 2 of these deaths (4%) were sudden, whereas
41 patients (39%) in group 3 died and 35 of these deaths
(34%) were sudden.
Individual criteria of the beneficial response. To eval-
uate each variable in the "beneficial response" definition,
symptoms during ventricular tachycardia as well as the change
in ventricular tachycardia cycle length were examined in-
dividually. Of 97 patients who had only mild symptoms
during induced ventricular tachycardia at follow-up study,
46 (47%) had a recurrence, 25 (26%) died and sudden death
occurred in 19 (20%). Thirteen patients had severe symp-
toms during induced ventricular tachycardia despite having
an increase in tachycardia cycle length of 2:100 ms; six
(46%) of these patients died, five suddenly. To determine
whether ventricular tachycardia cycle length at follow-up
study alone could predict a favorable outcome (independent
of symptoms during ventricular tachycardia), two additional
patient groups were examined. Fifty patients had a ventric-
ular tachycardia cycle length of 2:400 ms at follow-up study;
sustained arrhythmia occurred in 23 (46%) and sudden death
occurred in 7 (14%). Twenty-four patients had a ventricular
tachycardia cycle length of 2:450 ms at follow-up study; 12
(50%) had a recurrence and 3 (13%) died suddenly (Table
4).
No differences were noted between patients taking amio-
darone and those receiving other therapy in arrhythmia re-
currence, total mortality or sudden death.
Discussion
Role of electrophysiologic testing. It has been previ-
ously demonstrated (1-15) that electrophysiologic testing is
useful in identifying patients at risk of recurrent ventricular
tachycardia or ventricular fibrillation, or both, and that the
results of programmed stimulation may be predictive of the
response to antiarrhythmic therapy. In this study we iden-
tified a group of patients with persistent vulnerability to
inducible sustained ventricular tachyarrhythmias in whom
the clinical outcome with respect to mortality and particu-
larly sudden death resembles the course of patients in whom
arrhythmia induction is prevented by drug therapy. Al-
though the incidence of arrhythmia recurrence in this in-
vestigation did not differ between groups showing a bene-
ficial response to antiarrhythmic therapyand thosenot showing
this response, total mortality and the incidence of sudden
death did differ significantly. This suggests that arrhythmia
recurrence is more often a nonfatal event in patients dem-
onstrating a beneficial response.
Arrhythmia recurrence and mortality on follow-up.
Among patients who continued to have inducible arrhythmia
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When total mortality was the statistical end point, there
was a significant difference between groups 2 and 3 (Fig.
2) (p < 0.002). The incidence of sudden cardiac death was
also significantly different between groups 2 and 3 (p <
0.0003) (Fig. 3). There was no difference in either total
mortality or sudden cardiac death between patients who no
longer had inducible arrhythmia (group I) and those who
demonstrated a beneficialresponse to antiarrhythmic therapy
(group 2).
The clinical end pointsfor the duration ofthe entire study
period are summarized in Table 4. In group 2, in which a
beneficial response occurred, 20 (39%) of 51 patients had
90
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at follow-up study, 30 to 40% of those who demonstrated
a beneficial response to drug therapy had arrhythmia re-
currence during the first 2 years of clinical follow-up. This
incidence is similar to the 40 to 50% recurrence rate seen
in patients not showing benefit of antiarrhythmic therapy.
However, total mortality and the occurrence of sudden death
events differed significantly between these two groups. Sur-
vival at 1 and 2 years in the beneficial response group was
94 and 82%, respectively, compared with 78 and 62% in
the group not showing any benefit. Sudden death occurred
in 4% of patients in the beneficial response group during
the entire follow-up period, compared with I and 2 year
sudden death event rates of 19 and 36%, respectively, in
the no benefit group.
Role of increased cycle length versus symptomatic
response. The effect of an increase in induced ventricular
tachycardia cycle length, independent of symptoms produced
during ventricular tachycardia, was not as striking in its
influence on total mortality and sudden death events. Pa-
tients who had a ~ 1()() ms increase in ventricular tachycardia
cycle length, but who still had severe symptoms during
ventricular tachycardia, had the highest rate of recurrence
and their mortality and sudden death event rates were iden-
tical to those of the patients who showed no benefit of
therapy. Patients who had mild symptoms during induced
sustained ventricular tachycardia but did not meet the cycle
length criterion fared slightly better than did patients who
had no benefit, but the differences were small and not sig-
nificant. The good clinical outcome observed in patients
who demonstrated the beneficial response appeared to re-
quire achieving both criteria of the response.
Limitations of study. This study has several limitations .
The amiodarone group was large although comparisons of
amiodarone-treated patients with those not taking amioda-
rone did not demonstrate significant differences. Regimens
that demonstrated a beneficial response were not used on a
long-term basis in some patients because amiodarone was
usually the last drug tested in an attempt to establish a
regimen that prevented initiation of ventricular tachycardia.
In these patients amiodarone was often used on a long-term
basis. If amiodarone produced a beneficial response it was
continued even though a beneficial response was observed
with a previously tested regimen. If amiodarone failed to
produce a beneficial response and another regimen did achieve
this result, the latter regimen was used on a long-term basis.
This study was a retrospective analysis of data, although
criteria for improvement or beneficial response Were se-
lected prospectively, before review and analysis.
Reduction in total mortality. Most investigators (1-15)
have reported the recurrence or sudden death rate, or both,
but not total mortality in patients in studies similar to ours.
It is thus interesting to note that total mortality is also sig-
nificantly reduced in patients in whom ventricular tachy-
cardia induction is prevented by drug therapy. This study
also extends the follow-up experience with regimens se-
lected for treatment of ventricular tachycardia to periods of
> 3 years. This study substantiates that regimens identified
as effective remain protective for several years.
Factors that determine the symptoms and clinical im-
pact of ventricular tachyarrhythmias. This study raises
several interesting and interrelated questions: why should
patients with mild symptoms not have a good clinical out-
come if the tachycardia cycle length did not increase> 100
ms, and why are cycle length criteria alone not sufficient
to identify a beneficial response? This study was not de-
signed to specifically answer these questions; however, some
speculation seems appropriate. It is clear that the hemo-
dynamic consequences of a ventricular tachycardia are due
to an interaction between the cycle length of the arrhythmia
and the underlying cardiac status, but the cycle length ap-
pears to be of prime importance (16-18). Symptoms such
as syncope (16) and cardiac arrest (17) as well as the systolic
blood pressure (18) during ventricular tachycardia have been
shown to correlate with the cycle length. However, the
hemodynamics of ventricular tachycardia are undoubtedly
complex and not completely understood (19,20). Stability
of ventricular tachycardia, ischemia produced by the rapid
rate and other factors that may evolve during an episode of
arrhythmia, have not been well studied. It appears that the
combination of an increase in cycle length and a reduction
in symptoms during tachycardia are needed to assure a less-
ening of the risk of sudden death.
Implications. Analyses of clinical end points of total
mortality and sudden death for patients who no longer had
inducible arrhythmia at electrophysiologic follow-up study
as well as for patients who demonstrated a beneficial re-
sponse to antiarrhythmic therapy were not significantly dif-
ferent. Thus, patients who demonstrate a benefit of anti-
arrhythmic therapy at electrophysiologic testing can be
expected to have recurrence of ventricular tachycardia at
the same rate as that of other patients in whom the arrhyth-
mia remains inducible but these recurrences, will not be
life-threatening events in most cases; arrhythmias will likely
resemble the arrhythmias induced at follow-up study.
Noninducibility should remain the current reference stan-
dard for defining effective antiarrhythmic regimens. Dem-
onstration of a beneficial response with one agent early in
the evaluation of an individual patient should not preclude
the search for an agent that achieves noninducibility. If
prevention of tachycardia induction cannot be achieved,
however, a beneficial response may be an acceptable alter-
native depending on the clinical situation.
Finally, if noninducibility or a beneficial response cannot
be demonstrated, alternative therapeutic options should be
actively explored. The I, 2 and 3 year mortality rates for
this group of patients are very high and alternatives to med-
ical therapy such as antitachycardia devices or surgery may
offer benefit for some.
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